Anbogen Therapeutics Secures $7.3M to Propel ABT-301 Cancer Therapy to Phase II Trials
Anbogen Therapeutics, a leading name in cancer therapeutics development, has announced the successful completion of an oversubscribed A+ round financing, securing USD 7.3 million to advance their groundbreaking cancer treatment, ABT-301. This latest funding round follows on the heels of a USD 12.5 million Series A round earlier this year, bringing Anbogen’s total funding to…